1. Japan Stocks

  2. •

    Consumer Cyclical

  3. •

    Residential Construction
FORLIFE Co., Ltd.

FORLIFE Co., Ltd.

3477.T
FORLIFE Co., Ltd.JP flagTokyo Stock Exchange
844.00
JPY
-1.00
- -
3.38BMarket Cap
FORLIFE Co., Ltd.
3477.T
(Tokyo Stock Exchange)

Recent

price

844.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
1,176.25
1,424.28
1,899.62
2,165.09
1,994.57
2,407.97
2,691.75
3,090.44
3,529.29
3,497.65
3,693.57
- -
1,813.08
Revenue per Share
32.49
68.08
101.65
64.41
34.23
52.49
94.92
120.09
58.97
37.83
137.72
- -
41.23
Basic EPS, GAAP
-166.93
-48.32
168.44
-18.45
-98.3
-47.62
-11.49
-134.62
-37.89
97.66
-185.93
- -
- -
Free Cash Flow per Basic Share
- -
- -
4.14
20
15.01
14.99
20
19.99
23.99
10
12.5
- -
- -
Dividend per Share
361.89
429.97
502.57
547.8
567.05
604.55
679.47
779.59
814.55
842.38
967.61
- -
903.17
Book Value per Share
361.23
428.34
570.3
571.52
591.28
628.27
702.77
803.43
838.87
867.38
991.54
- -
928.17
Tangible Book Value per Share
4
4
4
4
4
4
4
4
4
4
4
- -
4
Basic Weighted Avg Shares
4,235
5,127
7,025
8,659
7,977
9,630
10,765
12,359
14,114
13,988
14,771
17,476
7,251
Sales/Revenue/Turnover
7.84
9.71
8.21
4.41
3.06
3.44
5.69
6.06
2.75
1.87
4
5.04
3.45
Operating Margin (%)
9
12
16
24
34
32
19
17
23
20
20
19
- -
Depreciation Expense
117
245
376
258
137
210
380
480
236
151
551
544
165
Net Income, GAAP
37.58
30.81
32.13
30.83
37.07
31.39
34.28
32.61
28.34
28.32
33.29
30.86
27.08
Effective Tax Rate (%)
2.76
4.78
5.35
2.97
1.72
2.18
3.53
3.89
1.67
1.08
3.73
3.11
2.27
Profit Margin (%)
1,110
1,420
2,003
2,051
2,325
2,403
3,129
3,322
3,270
3,158
3,746
4,053
3,526
Working Capital
244
123
144
85
254
180
610
432
404
568
105
34
140
LT Debt
1,303
1,548
2,118
2,295
2,372
2,522
2,822
3,222
3,362
3,473
3,974
4,358
3,716
Total Equity
- -
13.34
13.92
7.97
3.86
5.19
7.87
8.1
3.91
2.56
5.02
6.77
2.34
Return on Invested Capital (%)
- -
10.2
14.86
8.74
3.93
5.37
8.25
8.58
4.02
2.71
7.88
7.06
2.44
Return on Capital (%)
- -
17.2
22.07
12.72
6.14
8.96
14.78
16.46
7.4
4.57
15.22
13.4
4.84
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
ST Debt
3,062
- -
4,485
LT Borrowings
565
- -
140
LT Finance Leases
3
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
4
- -
4
Market Capitalization
2,380
2,404
2,400

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
Total Current Assets
7,003
- -
9,060
Cash, Cash Equivalents & STI
2,446
- -
2,616
Accounts Receivable, Net
- -
- -
- -
Inventories
4,215
- -
5,901
Total Current Liabilities
3,845
- -
5,533
Payables & Accruals
- -
- -
- -
ST Debt
3,062
- -
4,485
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.27%
9.19%
9.67%
Free Cash Flow
2.3%
57.54%
-63.76%
Net Income, GAAP
31.19%
40.53%
-1.17%
Sales/Revenue/Turnover
13.69%
10.4%
18.31%
Total Cash Common Dividend
- -
41.29%
219.77%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,896
3,841
3,466
3,785
13,988
2025
- -
- -
- -
- -
14,771
2026
- -
- -
- -
- -
17,476

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-3.64
- -
- -
- -
37.83
2025
- -
- -
- -
- -
137.72
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
10
2025
- -
- -
- -
- -
12.5
2026
- -
- -
- -
- -
- -
Similar Companies
Persimmon Plc (PSMMF)
D.R. Horton, Inc. (0I6K.L)
Vaghani Techno-Build Limited (VAGHANI.BO)
Sekisui House, Ltd. (1928.T)
The Berkeley Group Holdings plc (BKGFF)
Persimmon Plc (PSMMY)
Business
FORLIFE Co., Ltd. is a medical device company specializing in the design, development, manufacturing, and distribution of high-quality healthcare products with a core focus on ostomy care, continence care, wound care, and enteral nutrition products. Founded in 1990 and headquartered in Berlin, Germany, the company manufactures specialized medical devices and aids designed to improve the health and quality of life for people with stoma, continence, nutritional, and wound care needs. Its product portfolio includes ostomy care products such as stoma bags and accessories, continence care items, wound dressings, and supportive enteral nutrition products. FORLIFE collaborates closely with patients and healthcare professionals to ensure its products address intimate medical needs effectively. In December 2024, FORLIFE underwent a significant ownership change when it was acquired by European private equity firm Duke Street from GHD GesundHeits GmbH, Germany's largest outpatient health, therapy, and service company. This acquisition included FORLIFE's development and production center in Berlin along with its UK distributor Oakmed. Simultaneously, Duke Street acquired the assets of Trio Healthcare Ltd., a UK-based specialist in stoma care, adding innovative products such as Genii™ stoma bags featuring Sil2 Breathable Silicone Technology® to FORLIFE’s portfolio. This strategic combination aims to create a leading player in the European ostomy care market, enhancing product development capabilities and expanding distribution reach across European markets. FORLIFE operates primarily in Germany and the UK markets and is positioned within the healthcare and medical devices industry, focusing on ostomy, continence, wound care, and nutrition support segments. The company's strategic alliance with Trio Healthcare broadens its product offering and technological innovation, strengthening its market position. The company is part of a portfolio supported by Duke Street, which plans to leverage its investment to drive growth and operational improvements in the healthcare sector with emphasis on product innovation and expanded distribution capacity. This comprehensive operational and strategic profile positions FORLIFE as a specialist healthcare company dedicated to delivering patient-centered medical devices and solutions in the European market. The company's latest changes reflect a notable shift in ownership and an expansion through acquisition, aiming to solidify its leadership in ostomy care and related healthcare products across Europe.